This Is MS Multiple Sclerosis Knowledge & Support Community

Analysis of nicergoline in treating elderly chronic cerebrospinal venous insufficiency

(1. Department of Neurology, China Meitan General Hospital, Beijing
100028, China; 2. Department of Emergency, The First Affiliated Hospital of Henan University of Science and
Technology, Henan, Luoyang 471000, China)

Abstract 【Abstract】 Objective　To investigate the clinical effect of nicergoline in treatment of elderly patients with
chronic cerebrospinal venous insufficiency.

Method　Used random number table method to selected 162cases of elderly patients with chronic cerebrovascular venous insufficiency from July 2012 to July 2014 in
our hospital as research objects, they were divided into nicergoline group and routine group, 81 cases in each
group. Routine group patients were treated with conventional methods, on the basis of conventional treatment,
nicergoline group patients were treated with nicergoline. Clinical effects of the two groups were compared.

Result　Before treatment, the index [color Doppler ultrasound detection of vertebral artery and middle cerebral
artery, the end diastolic velocity (Vd), peak systolic velocity (Vs), resistance index (RI), pulsatility index (PI)]
were not significant different (P ＞ 0.05); 12 weeks after treatment, Vd, Vs, RI, PI of the two groups patients
were significantly improved than before treatment, the difference was significant (P ＜ 0.05), and Vd, Vs, RI, PI
of nicergoline group patients were superior to control group, the difference was significant (P ＜ 0.05). MMSE
scores of the two groups patients before treatment were not significant different (P ＞ 0.05); after treatment,
MMSE scores of the two groups patients were significantly increased than before treatment (P ＜ 0.05), and
MMSE scores of nicergoline group was (24.5±1.3) points, significantly higher than routine group [(22.9±1.5)
points], the difference was significant (P ＜ 0.05). 12 weeks after treatment, total effective rate of nicergoline
group was 91.36%, significantly higher than routine group (76.54%), the difference was significant (P ＜ 0.05).

Conclusion　Nicergoline can improve patients with elderly chronic cerebrospinal venous insufficiency clinical
symptoms and brain blood flows, and can significantly improve the clinical treatment effect.

[6] Simka M, Kostecki J, Zaniewski M, et al. Extracranial Doppler
sonographic criteria of chronic cerebrospinal venous insufficiency
in the patients with multiple sclerosis [J]. Int Angiol,
2010, 29 (12): 109-114.

CureOrBust wrote:I was surprised at how simply they stated CCSVI as if it was a commonly known condition, so I looked at the cited articles

jencor69 wrote:

CureOrBust wrote:I was surprised at how simply they stated CCSVI as if it was a commonly known condition, so I looked at the cited articles

I am not quite sure why you were surprised to see CCSVI stated simply. In 2009 A Consensus Conference on Venous Malformations - headed by Prof. Byung B Lee from Georgetown - and experts from 47 countries- studied the evidence and unanimously voted in favour of officially including the stenosing lesions found in CCSVI in the new Consensus document and Guidelines. It IS a commonly known condition. Now published-

http://www.ncbi.nlm.nih.gov/pubmed/2008 ... dinalpos=1

Rosegirl wrote:Anyone know how old "elderly" is?